- Takeda to invest €40M in a new facility at Grange Castle, Dublin.
- The facility will manufacture the oncology product NINLARO™.
- The investment will create approximately 40 new jobs.
- Supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.
Investment Announcement
Minister for Jobs, Enterprise and Innovation Mary Mitchell O’Connor TD announced that Takeda Pharmaceutical Company Limited will invest €40M in a new facility at their Grange Castle site in Dublin. This investment will expand the existing footprint with a standalone high containment production facility dedicated to manufacturing the oncology product NINLARO™ for global markets.
Job Creation
The investment will create approximately 40 new jobs at the Grange Castle site. This development is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.
Takeda's Presence in Ireland
Takeda, the largest pharmaceutical company in Japan, first established operations in Ireland in 1997. In 2002, Dublin was chosen as the location for Takeda's first active pharmaceutical ingredient (API) facility outside of Japan.
Government and Industry Support
Minister Mitchell O'Connor highlighted the significant contribution of the pharma industry to the Irish economy in terms of jobs and exports. She noted that Takeda's decision to manufacture their new cancer treatment in Ireland is a strong vote of confidence in the country’s expanding pharma sector.
Industry Recognition
Martin Shanahan, CEO of IDA Ireland, emphasized that Ireland is a globally recognized center of excellence in life sciences, citing the country’s strong regulatory track record and talent availability. He stated that Takeda's investment demonstrates their continued commitment to Ireland.
